Oncimmune Holdings plc, the leading global immunodiagnostics group, today announces that it has sold its wholly-owned subsidiaries, Oncimmune Limited (including the CEmarked IVD EarlyCDT® Lung blood test, antibody platform and research and development pipeline) and Oncimmune Europe GmbH to Freenome Holdings, Inc. for a total of £13M in cash.
Oncimmune will continue to operate its ImmunoINSIGHTS business, primarily through its subsidiary Oncimmune Germany GmbH.